Skip to main contentSkip to navigationSkip to search

Press release

Camurus Annual Report for 2019

08 April 2020 | Regulatory

Lund, Sweden — 8 April 2020 — Camurus today announces that the Annual Report for 2019 now is available at the company’s website: www.camurus.com

For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92

fredrik.tiberg@camurus.com

Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com

About Camurus
Camurus is a Swedish, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit camurus.com.

TypeError: Cannot read properties of undefined (reading 'url')